Immunology and Microbiology
Immunoglobulin E
100%
Allergen
83%
Birch Pollen
29%
Sensitization
23%
Melanoma Cell
22%
Molecular Weight
21%
Allergenicity
19%
Peptides
18%
Holocephali
18%
ELISA
16%
Epitope
15%
Extract
15%
Basophil
14%
Escherichia coli
13%
Cross-Reactivity
12%
Hypersensitive Response
12%
Monoclonal Antibody
10%
B Cell
10%
Squamous Cell
10%
Allergen Specific Immunotherapy
10%
Proinflammatory Cytokine
10%
Talimogene Laherparepvec
9%
Permeability Barrier
9%
Nicotiana benthamiana
9%
Cell Invasion
9%
Sorafenib
9%
Peptide Library
9%
Notch
9%
Lactobacillus buchneri
9%
Antigen Presentation
9%
Nose Mucosa
9%
Western Blot
9%
Chondroitin Sulfate Proteoglycan
9%
Cell Surface
9%
Notch Signaling
9%
Programmed Death-Ligand 1
9%
Salmon
9%
DNA Repair
9%
Salmonine
9%
Tumor Spheroid
9%
Neutrophil
9%
Cell Adhesion Proteins
9%
Cadherin
9%
Bacteriophage
9%
Transcriptomics
9%
Mimotope
9%
Basophil Activation
7%
Mediator
7%
In Vitro
7%
T Cell
7%
Medicine and Dentistry
Melanoma
40%
Metastatic Melanoma
24%
Skin Carcinoma
18%
Neoplasm
15%
Carcinogenesis
10%
Melanoma Cell
10%
Tumor
9%
Diseases
9%
Proteochondroitin Sulfate
9%
B Cell
9%
Sorafenib
9%
Hepatocellular Carcinoma
9%
Cancer Therapy
9%
Therapy Resistance
9%
Tumour Heterogeneity
9%
DNA Repair
9%
Mammalian Cell
9%
Skin Biopsy
9%
Notch Signaling
9%
Aminolevulinic Acid
9%
Nivolumab
9%
Uvomorulin
9%
Allergology
9%
Programmed Death 1 Receptor
9%
Hemosiderin
9%
Pigmentation
9%
Melanocytosis
9%
Hematologic Malignancy
9%
Notch
9%
Progression Free Survival
8%
In Vitro
7%
Biopsy Technique
6%
Malignant Neoplasm
6%
Clinical Trial
6%
Tumor Progression
6%
Magnetic Resonance Imaging
6%
Meningitis
6%
Overall Survival
5%
Immunoglobulin E
5%
Allergen
5%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
37%
Skin Carcinoma
18%
Nivolumab
16%
Progression Free Survival
16%
Diseases
15%
Overall Survival
13%
Metastatic Melanoma
13%
Mitogen Activated Protein Kinase Kinase Inhibitor
12%
Trametinib
10%
Dabrafenib
10%
Pembrolizumab
9%
EC50
9%
Talimogene Laherparepvec
9%
Aminolevulinic Acid
9%
Hemosiderin
9%
Chondroitin Sulfate
9%
Lactobacillus buchneri
9%
Allergen
9%
Immunotherapy
9%
Programmed Death 1 Receptor
9%
Hematologic Malignancy
9%
Peanut
9%
Skin Cancer
9%
Immunoglobulin E
9%
Adverse Event
7%
Malignant Neoplasm
6%
Chimeric Protein
6%
Survival Rate
5%
Recurrent Disease
5%
